Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 759 articles:
HTML format



Single Articles


    July 2022
  1. BARCENA-VARELA M
    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.
    PubMed    


  2. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.
    PubMed    


  3. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    PubMed     Abstract available


  4. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    PubMed     Abstract available


  5. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.
    PubMed    


  6. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.
    PubMed    


    June 2022
  7. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available


  8. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    PubMed    


  9. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
    PubMed    


  10. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    


  11. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    PubMed     Abstract available


  12. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    PubMed    


  13. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    PubMed    


  14. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
    PubMed    


  15. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    PubMed    



  16. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
    PubMed    


  17. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    


  18. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    PubMed     Abstract available


  19. CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
    Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
    J Hepatol. 2022;76:1348-1361.
    PubMed     Abstract available


  20. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    PubMed     Abstract available


  21. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    PubMed     Abstract available


  22. TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
    Breakthroughs in hepatology.
    J Hepatol. 2022;76:1247-1248.
    PubMed    


  23. GARDIN A, Remih K, Gonzales E, Andersson ER, et al
    Modern therapeutic approaches to liver-related disorders.
    J Hepatol. 2022;76:1392-1409.
    PubMed     Abstract available


  24. BAJAJ JS, Ng SC, Schnabl B
    Promises of microbiome-based therapies.
    J Hepatol. 2022;76:1379-1391.
    PubMed     Abstract available


  25. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    PubMed     Abstract available


  26. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    PubMed     Abstract available


    May 2022
  27. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    PubMed     Abstract available


  28. MOLINA L, Zhu J, Trepo E, Bayard Q, et al
    Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
    PubMed     Abstract available


  29. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
    PubMed     Abstract available


  30. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    PubMed    


  31. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    PubMed     Abstract available


  32. DING WX, Ni HM, Waguri S, Komatsu M, et al
    Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
    PubMed    


  33. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    PubMed    


  34. HUSAIN A, Chiu YT, Oi-Lin Ng I
    EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
    PubMed    


  35. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    


  36. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    PubMed    


  37. SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
    Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
    PubMed     Abstract available


  38. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    PubMed    


  39. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    PubMed    


  40. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
    PubMed    


  41. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
    PubMed    


  42. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    PubMed    


  43. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
    PubMed    


  44. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
    J Hepatol. 2022;76:995-1000.
    PubMed    


  45. REIG M, Bruix J
    Reply to: "Correspondence on the ".
    J Hepatol. 2022;76:1240-1241.
    PubMed    


  46. PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;76:1021-1029.
    PubMed     Abstract available


  47. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    PubMed     Abstract available


  48. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    PubMed     Abstract available


  49. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    PubMed     Abstract available


  50. XU X, Lau WY, Yang T
    The updated BCLC staging system needs further refinement: A surgeon's perspective.
    J Hepatol. 2022;76:1239-1240.
    PubMed    


  51. MARJOT T, Ray DW, Tomlinson JW
    Is it time for chronopharmacology in NASH?
    J Hepatol. 2022;76:1215-1224.
    PubMed     Abstract available


  52. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    PubMed     Abstract available


  53. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    PubMed     Abstract available


  54. BERRY P, Kotha S
    Improving end of life care in liver disease.
    J Hepatol. 2022;76:1225-1226.
    PubMed    


  55. ELHENCE A, Shalimar
    Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
    J Hepatol. 2022;76:1236-1237.
    PubMed    


  56. GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
    Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:1001-1012.
    PubMed     Abstract available


    April 2022
  57. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    PubMed    


  58. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    PubMed    


  59. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    PubMed    


  60. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    PubMed     Abstract available


  61. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    PubMed     Abstract available


  62. ZHANGYUAN G
    Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
    PubMed    


  63. JIANG X, Fulte S, Deng F, Chen S, et al
    Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
    PubMed     Abstract available


  64. ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
    Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
    PubMed     Abstract available


  65. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
    PubMed    


  66. CHUAH S, Lee J, Song Y, Kim HD, et al
    Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
    PubMed     Abstract available


  67. LI C, Ouyang W, Yang T
    The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
    PubMed    


  68. CHAPIRO J
    Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
    PubMed    


  69. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    PubMed     Abstract available


  70. RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
    HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
    PubMed     Abstract available


  71. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
    PubMed    


  72. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
    PubMed    


  73. DEMIR M, Lang S, Hartmann P, Duan Y, et al
    The fecal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:788-799.
    PubMed     Abstract available


  74. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    PubMed    


  75. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    PubMed     Abstract available


  76. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    PubMed    


  77. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    PubMed     Abstract available


  78. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    PubMed     Abstract available


  79. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    PubMed     Abstract available


  80. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    PubMed     Abstract available


    March 2022
  81. BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
    T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
    PubMed     Abstract available


  82. WANG S, Wu Q, Chen T, Su R, et al
    Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
    PubMed     Abstract available


  83. LI D, Yi C, Huang H, Li J, et al
    Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
    PubMed    


  84. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    PubMed     Abstract available


  85. JALAN R, Rose CF
    Heretical thoughts into Hepatic Encephalopathy.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
    PubMed     Abstract available


  86. BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
    Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
    PubMed     Abstract available


  87. LIN P, Yang H
    EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
    PubMed    


  88. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    PubMed     Abstract available


  89. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    PubMed    


  90. YANG Y, Ouyang J, Zhou Y, Zhou J, et al
    The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
    PubMed    


  91. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    PubMed    


  92. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    PubMed    


  93. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    PubMed    


  94. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available


  95. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    PubMed     Abstract available


  96. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    PubMed    


  97. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    PubMed    


  98. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    PubMed    


  99. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    PubMed    


  100. SUN X, Wu J, Liu L, Chen Y, et al
    Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
    J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
    PubMed     Abstract available


  101. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    PubMed     Abstract available


  102. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    PubMed     Abstract available


  103. LOESCH R, Caruso S, Paradis V, Godard C, et al
    Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
    J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
    PubMed     Abstract available



  104. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    PubMed     Abstract available


  105. SPELIOTES EK, George J
    Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    J Hepatol. 2022;76:498-500.
    PubMed    


  106. DING WX, Sancho-Bru P
    SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
    J Hepatol. 2022;76:503-505.
    PubMed    


  107. MARTINEZ J, Hernandez-Gea V, Albillos A
    Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
    J Hepatol. 2022;76:752-753.
    PubMed    


  108. SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
    Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;76:739-740.
    PubMed    


  109. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    PubMed    


  110. EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
    The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
    J Hepatol. 2022;76:738-739.
    PubMed    


  111. LIU D, Zhang Q, Bai P, Zhao J, et al
    Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:740-742.
    PubMed    


  112. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    


  113. ALABSAWY E, Shalimar, Jalan R
    Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
    J Hepatol. 2022;76:751-752.
    PubMed    



  114. Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
    J Hepatol. 2022;76:758.
    PubMed    


  115. GUO B, Guo Y, Nima Q, Feng Y, et al
    Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2022;76:518-525.
    PubMed     Abstract available


  116. REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
    BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
    J Hepatol. 2022;76:681-693.
    PubMed     Abstract available


  117. KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
    Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
    J Hepatol. 2022;76:665-680.
    PubMed     Abstract available


  118. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    PubMed     Abstract available


  119. RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
    EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    J Hepatol. 2022;76:506-517.
    PubMed     Abstract available


  120. LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
    Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:526-535.
    PubMed     Abstract available


  121. YIP TC, Lee HW, Chan WK, Wong GL, et al
    Asian perspective on NAFLD-associated HCC.
    J Hepatol. 2022;76:726-734.
    PubMed     Abstract available


    February 2022
  122. HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
    Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
    J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
    PubMed     Abstract available


  123. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
    PubMed    


  124. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
    PubMed     Abstract available


  125. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    PubMed     Abstract available


  126. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    PubMed     Abstract available


  127. OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
    Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
    J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
    PubMed    


  128. SCHEINER B, Pinter M
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
    J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
    PubMed    


  129. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    PubMed     Abstract available


  130. JEONG J, Tanaka M, Iwakiri Y
    Hepatic lymphatic vascular system in health and disease.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
    PubMed     Abstract available


  131. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available


  132. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
    PubMed    


  133. ZINGONI A, Banales JM
    PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
    J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
    PubMed    


  134. ZENG Q, Klein C, Caruso S, Maille P, et al
    Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
    PubMed     Abstract available


  135. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    PubMed     Abstract available


  136. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available


  137. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    PubMed    


  138. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    PubMed    


  139. KIM D, Ahmed A
    Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
    J Hepatol. 2022;76:477-478.
    PubMed    


  140. FOUAD YM, Mendez-Sanchez N, Zheng MH
    One not like the other: The weakness of the blood sugar-MAFLD analogy.
    J Hepatol. 2022;76:482-484.
    PubMed    


  141. DE A, Ahmad N, Mehta M, Singh P, et al
    NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
    J Hepatol. 2022;76:475-477.
    PubMed    


  142. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    PubMed    


  143. WANG YZ
    MAFLD supported by 95.45% participants of CSH is NOT representative.
    J Hepatol. 2022;76:481-482.
    PubMed    


  144. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    PubMed     Abstract available


  145. DANA J, Debray D, Beaufrere A, Hillaire S, et al
    Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    J Hepatol. 2022;76:420-434.
    PubMed     Abstract available


  146. MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
    Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
    J Hepatol. 2022;76:265-274.
    PubMed     Abstract available


  147. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    PubMed     Abstract available


    January 2022
  148. YANG M, Wu X, Hu J, Wang Y, et al
    COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
    PubMed     Abstract available


  149. BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
    Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
    PubMed     Abstract available


  150. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    PubMed    


  151. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    PubMed     Abstract available


  152. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    PubMed     Abstract available


  153. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    PubMed     Abstract available


  154. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    PubMed    


  155. ZHOU HF, Yang W, Zhou WZ
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
    J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
    PubMed    


  156. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    PubMed    


  157. CRAMER T, Vaupel P
    Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
    PubMed     Abstract available


  158. JAGADISAN B, Dhawan A
    Emergencies in Pediatric hepatology.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
    PubMed     Abstract available


  159. MALLET V, Schwarzinger M
    Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
    J Hepatol. 2022;76:229-230.
    PubMed    


  160. LONG J, Sang X, Zhao H
    Association of chronic liver disease with the prognosis of COVID-19 patients.
    J Hepatol. 2022;76:228-229.
    PubMed    


  161. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    PubMed    


  162. SCHUPPAN D, Myneni S, Surabattula R
    Liquid biomarkers for fibrotic NASH - progress in a complex field.
    J Hepatol. 2022;76:5-7.
    PubMed    



  163. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
    J Hepatol. 2022;76:251-252.
    PubMed    


  164. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    PubMed    


  165. TURON F, Lisman T, Carlos-Garcia-Pagan J
    Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
    J Hepatol. 2022;76:227-228.
    PubMed    


  166. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    PubMed    


  167. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    PubMed    


  168. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    PubMed    


  169. LIU Y, Liu C, Li J, Kim TH, et al
    Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
    J Hepatol. 2022;76:248-250.
    PubMed    


  170. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    PubMed     Abstract available


  171. DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
    J Hepatol. 2022;76:11-24.
    PubMed     Abstract available


  172. VOGEL A, Saborowski A
    Medical therapy of HCC.
    J Hepatol. 2022;76:208-210.
    PubMed    


  173. LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
    An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
    J Hepatol. 2022;76:247-248.
    PubMed    


  174. SINGAL AG, El-Serag HB
    Rational HCC screening approaches for patients with NAFLD.
    J Hepatol. 2022;76:195-201.
    PubMed     Abstract available


  175. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    PubMed     Abstract available


  176. SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
    HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    J Hepatol. 2022;76:53-62.
    PubMed     Abstract available


  177. ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
    Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
    J Hepatol. 2022;76:93-106.
    PubMed     Abstract available


  178. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    PubMed    


    December 2021
  179. SCHEINER B, Pinter M
    Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
    J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
    PubMed    


  180. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    PubMed     Abstract available


  181. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    PubMed    


  182. WANG H, Zhang S, Zhang Y, Jia J, et al
    Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
    PubMed    


  183. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available


  184. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    PubMed    


  185. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    PubMed     Abstract available


  186. TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
    Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
    J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
    PubMed     Abstract available


  187. WANG X, Zeldin S, Shi H, Zhu C, et al
    TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
    PubMed     Abstract available


  188. CHENG AL, Qin S, Ikeda M, Galle PR, et al
    Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
    PubMed     Abstract available


  189. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    


  190. KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
    Michael Charles Kew - Frontrunner in Hepatology.
    J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
    PubMed    


  191. KADONO K, Kageyama S, Nakamura K, Hirao H, et al
    Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
    PubMed     Abstract available


  192. NACHIT M, Kwanten WJ, Francque S
    Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
    J Hepatol. 2021;75:1513-1514.
    PubMed    


  193. LUEDDE T, Baumann U, Keitel V
    Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
    J Hepatol. 2021;75:1502-1503.
    PubMed    


  194. WONG VW, Lazarus JV
    Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    J Hepatol. 2021;75:1267-1270.
    PubMed    


  195. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    PubMed    


  196. MATTHEWS C, Cross TJS
    Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
    J Hepatol. 2021;75:1494-1495.
    PubMed    


  197. KOTHA S, Berry P
    Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
    J Hepatol. 2021;75:1501-1502.
    PubMed    


  198. CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
    Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
    J Hepatol. 2021;75:1511-1513.
    PubMed    


  199. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    PubMed     Abstract available


  200. IOANNOU GN
    Epidemiology and risk-stratification of NAFLD-associated HCC.
    J Hepatol. 2021;75:1476-1484.
    PubMed     Abstract available


  201. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    PubMed     Abstract available


  202. HSU CL, Duan Y, Fouts DE, Schnabl B, et al
    Intestinal virome and therapeutic potential of bacteriophages in liver disease.
    J Hepatol. 2021;75:1465-1475.
    PubMed     Abstract available


  203. KIM D, Konyn P, Sandhu KK, Dennis BB, et al
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021;75:1284-1291.
    PubMed     Abstract available


  204. ENGELMANN C, Herber A, Franke A, Bruns T, et al
    Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
    J Hepatol. 2021;75:1346-1354.
    PubMed     Abstract available


  205. GADALETA RM, Moschetta A
    Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
    J Hepatol. 2021;75:1440-1451.
    PubMed     Abstract available


  206. D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
    Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
    J Hepatol. 2021;75:1355-1366.
    PubMed     Abstract available


    November 2021
  207. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    PubMed    


  208. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    PubMed     Abstract available


  209. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    PubMed     Abstract available


  210. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    PubMed     Abstract available


  211. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available


  212. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    PubMed     Abstract available


  213. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    PubMed    


  214. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    PubMed    


  215. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    PubMed     Abstract available


  216. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    PubMed    


  217. COLOMBO M, Barouki R
    Expanding the liver exposome: should hepatologists care about air pollution?
    J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
    PubMed    


  218. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    PubMed    


  219. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    PubMed     Abstract available


  220. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    PubMed    


  221. GUPTA P, Sharma V, Kalra N
    Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
    J Hepatol. 2021;75:1259-1260.
    PubMed    


  222. VILLANUEVA C, Bosch J
    Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
    J Hepatol. 2021;75:1242-1243.
    PubMed    


  223. KUTAIBA N, Ardalan Z
    Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
    J Hepatol. 2021;75:1258-1259.
    PubMed    


  224. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    PubMed    


  225. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    PubMed    


  226. REICHERT MC, Ripoll C
    First things first! Can bacterial infections be considered as decompensating events per se?
    J Hepatol. 2021;75:1241-1242.
    PubMed    


  227. LANGE NF, Radu P, Dufour JF
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021;75:1217-1227.
    PubMed     Abstract available


  228. HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
    Maternal obesity increases the risk and severity of NAFLD in offspring.
    J Hepatol. 2021;75:1042-1048.
    PubMed     Abstract available


  229. RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
    The multifaceted role of cathepsins in liver disease.
    J Hepatol. 2021;75:1192-1202.
    PubMed     Abstract available


  230. SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
    Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    J Hepatol. 2021;75:1034-1041.
    PubMed     Abstract available


  231. WANG Q, Liang N, Yang T, Li Y, et al
    DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
    J Hepatol. 2021;75:1142-1153.
    PubMed     Abstract available


  232. JALAN R, Gustot T, Fernandez J, Bernal W, et al
    'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
    J Hepatol. 2021;75:1228-1235.
    PubMed     Abstract available


  233. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    PubMed     Abstract available


  234. RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
    Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
    J Hepatol. 2021;75:1017-1025.
    PubMed     Abstract available


  235. LI F, Thuluvath PJ
    EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
    J Hepatol. 2021;75:1096-1103.
    PubMed     Abstract available


    October 2021
  236. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    PubMed     Abstract available


  237. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    PubMed     Abstract available


  238. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    PubMed     Abstract available


  239. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    PubMed     Abstract available


  240. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    PubMed     Abstract available


  241. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    PubMed     Abstract available


  242. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    PubMed     Abstract available


  243. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    PubMed    


  244. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    PubMed     Abstract available


  245. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    PubMed     Abstract available


  246. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    PubMed     Abstract available


  247. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    PubMed    


  248. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    PubMed    


  249. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    PubMed    


  250. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    PubMed    


  251. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    PubMed     Abstract available


  252. CHEN X, Chen S, Pang J, Tang Y, et al
    Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
    J Hepatol. 2021;75:987-989.
    PubMed    


  253. LACKNER C, Stauber RE, Davies S, Denk H, et al
    Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
    J Hepatol. 2021;75:810-819.
    PubMed     Abstract available


  254. YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
    Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:786-794.
    PubMed     Abstract available


  255. GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
    Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    J Hepatol. 2021;75:795-809.
    PubMed     Abstract available


  256. SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
    Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    J Hepatol. 2021;75:770-785.
    PubMed     Abstract available


    September 2021
  257. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    PubMed    


  258. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    PubMed     Abstract available


  259. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    PubMed     Abstract available


  260. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available


  261. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    PubMed     Abstract available


  262. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    PubMed     Abstract available


  263. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    PubMed     Abstract available


  264. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    PubMed    


  265. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    PubMed     Abstract available


  266. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available


  267. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    PubMed    


  268. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available


  269. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    PubMed    


  270. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    PubMed    


  271. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    PubMed    


  272. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    PubMed     Abstract available


  273. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    PubMed    


  274. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    PubMed    


  275. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    PubMed    


  276. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    PubMed    


  277. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    PubMed    


  278. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    PubMed    


  279. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    PubMed    



  280. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
    J Hepatol. 2021;75:659-689.
    PubMed     Abstract available


  281. YOO T, Joo SK, Kim HJ, Kim HY, et al
    Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:514-523.
    PubMed     Abstract available


  282. CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
    Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
    J Hepatol. 2021;75:506-513.
    PubMed     Abstract available


    August 2021
  283. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    PubMed     Abstract available


  284. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    PubMed    


  285. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    PubMed     Abstract available


  286. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    PubMed     Abstract available


  287. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    PubMed     Abstract available


  288. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    PubMed     Abstract available


  289. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    PubMed     Abstract available


  290. NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    J Hepatol. 2021;75:292-301.
    PubMed     Abstract available


  291. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    PubMed     Abstract available


  292. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    PubMed     Abstract available


  293. MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
    Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
    J Hepatol. 2021;75:342-350.
    PubMed     Abstract available


  294. YANG Y, Sangwung P, Kondo R, Jung Y, et al
    Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    J Hepatol. 2021;75:377-386.
    PubMed     Abstract available


    July 2021
  295. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    PubMed     Abstract available


  296. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    PubMed     Abstract available


  297. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available


  298. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    PubMed    


  299. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    PubMed    


  300. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    PubMed    


  301. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    PubMed     Abstract available


  302. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


  303. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    PubMed     Abstract available


  304. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    PubMed     Abstract available


  305. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    PubMed    


  306. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    PubMed     Abstract available


  307. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    PubMed    


  308. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    PubMed     Abstract available


  309. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    PubMed     Abstract available


  310. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    PubMed     Abstract available


  311. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    PubMed     Abstract available


  312. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    PubMed     Abstract available


  313. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    PubMed     Abstract available


  314. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    PubMed     Abstract available


  315. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    PubMed     Abstract available


  316. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    PubMed     Abstract available


  317. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    PubMed    


  318. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    PubMed    


  319. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    PubMed    


  320. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    PubMed    


  321. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    PubMed    


  322. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    PubMed    


  323. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    PubMed    


  324. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    PubMed    


  325. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    PubMed    


  326. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    PubMed    


  327. BEUERS U
    EASL recognition award recipient 2021: Prof. Dieter Haussinger.
    J Hepatol. 2021;75:7-9.
    PubMed    


  328. ROMERO-GOMEZ M
    EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
    J Hepatol. 2021;75:10-11.
    PubMed    


  329. MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
    Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
    J Hepatol. 2021;75:221-222.
    PubMed    


  330. PETERS L, Burkert S, Gruner B
    Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
    J Hepatol. 2021;75:202-218.
    PubMed     Abstract available


  331. SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
    Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
    J Hepatol. 2021;75:34-45.
    PubMed     Abstract available


  332. LIU C, Zhou B, Meng M, Zhao W, et al
    FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:150-162.
    PubMed     Abstract available


  333. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    PubMed     Abstract available


  334. GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
    Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
    J Hepatol. 2021;75 Suppl 1:S36-S48.
    PubMed     Abstract available


  335. MOREAU R, Gao B, Papp M, Banares R, et al
    Acute-on-chronic liver failure: A distinct clinical syndrome.
    J Hepatol. 2021;75 Suppl 1:S27-S35.
    PubMed     Abstract available


  336. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    PubMed     Abstract available


  337. BERNAL W, Karvellas C, Saliba F, Saner FH, et al
    Intensive care management of acute-on-chronic liver failure.
    J Hepatol. 2021;75 Suppl 1:S163-S177.
    PubMed     Abstract available


    June 2021
  338. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  339. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  340. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  341. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    PubMed     Abstract available


  342. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  343. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    PubMed    


  344. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    PubMed    


  345. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    PubMed    


  346. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    


  347. FLEMMING JA, Velez MP
    The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
    J Hepatol. 2021;74:1283-1285.
    PubMed    


  348. KUMAR R, Jalan R
    Reply to: "Failure to control variceal bleeding: Definition matters".
    J Hepatol. 2021;74:1492-1493.
    PubMed    


  349. BAIGES A, Bureau C, Garcia-Pagan JC
    Failure to control variceal bleeding: Definition matters.
    J Hepatol. 2021;74:1491-1492.
    PubMed    


  350. BERNAL W, McPhail MJ
    Acute liver failure.
    J Hepatol. 2021;74:1489-1490.
    PubMed    


  351. GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
    Targeting cell-intrinsic metabolism for antifibrotic therapy.
    J Hepatol. 2021;74:1442-1454.
    PubMed     Abstract available


  352. BRUIX J
    Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
    J Hepatol. 2021;74:1483-1488.
    PubMed     Abstract available


  353. BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
    Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    J Hepatol. 2021;74:1362-1372.
    PubMed     Abstract available


  354. CADOUX M, Caruso S, Pham S, Gougelet A, et al
    Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness.
    J Hepatol. 2021;74:1386-1397.
    PubMed     Abstract available


  355. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    PubMed     Abstract available


  356. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    PubMed     Abstract available


    May 2021
  357. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  358. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    PubMed    


  359. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    PubMed    


  360. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    PubMed    


  361. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available


  362. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    PubMed    


  363. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    PubMed     Abstract available


  364. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    PubMed     Abstract available


  365. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    PubMed     Abstract available


  366. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  367. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    PubMed     Abstract available


  368. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    PubMed     Abstract available


  369. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    PubMed     Abstract available


  370. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


  371. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    PubMed     Abstract available


  372. JOHNSON PJ
    In search of an evidence base for HCC surveillance: Purity or pragmatism?
    J Hepatol. 2021;74:1025-1027.
    PubMed    


  373. ARROYO V, Fernandez J, Moreau R
    Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
    J Hepatol. 2021;74:1265-1267.
    PubMed    


  374. COENRAAD MJ, Artru F
    Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
    J Hepatol. 2021;74:1015-1017.
    PubMed    


  375. ESLAM M, George J
    MAFLD: Now is the time to capitalize on the momentum.
    J Hepatol. 2021;74:1262-1263.
    PubMed    


  376. FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
    Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
    J Hepatol. 2021;74:1254-1256.
    PubMed    


  377. ALEM SA, Gaber Y, Abdalla M, Said E, et al
    Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
    J Hepatol. 2021;74:1261-1262.
    PubMed    


  378. KASPER P, Martin A, Lang S, Demir M, et al
    Hypertension in NAFLD: An uncontrolled burden.
    J Hepatol. 2021;74:1258-1260.
    PubMed    


  379. SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
    The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
    J Hepatol. 2021;74:1256-1258.
    PubMed    


  380. ZHANG Y, Lu Z, Zeng W, Zhao J, et al
    Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
    J Hepatol. 2021;74:1250-1253.
    PubMed    


  381. ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
    Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
    J Hepatol. 2021;74:1117-1131.
    PubMed     Abstract available


  382. WANG T, Chen K, Yao W, Zheng R, et al
    Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
    J Hepatol. 2021;74:1038-1052.
    PubMed     Abstract available


    April 2021
  383. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    PubMed    


  384. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    PubMed     Abstract available


  385. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    PubMed    


  386. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    PubMed     Abstract available


  387. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
    Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
    PubMed     Abstract available


  388. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    PubMed    


  389. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    PubMed     Abstract available


  390. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    PubMed     Abstract available


  391. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available


  392. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    PubMed    


  393. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    PubMed    


  394. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    PubMed    


  395. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    PubMed    


  396. DESSEIN A
    Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    J Hepatol. 2021;74:769-770.
    PubMed    


  397. COSTA D, Simbrunner B, Reiberger T
    Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
    J Hepatol. 2021;74:1000-1001.
    PubMed    


  398. HOBEIKA C, Fuks D
    Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:987-988.
    PubMed    


  399. HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
    NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
    J Hepatol. 2021;74:991-992.
    PubMed    


  400. ESLAM M, Ratziu V, George J
    Yet more evidence that MAFLD is more than a name change.
    J Hepatol. 2021;74:977-979.
    PubMed    


  401. ESLAM M, George J
    MAFLD: A holistic view to redefining fatty liver disease.
    J Hepatol. 2021;74:983-985.
    PubMed    


  402. ESLAM M, George J
    MAFLD: A game changer redefining fatty liver disease for adults and children.
    J Hepatol. 2021;74:992-994.
    PubMed    


  403. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    PubMed    


  404. ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
    Clinical utility of the MAFLD definition.
    J Hepatol. 2021;74:989-991.
    PubMed    


  405. DEBNATH P, Rathi P
    Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
    J Hepatol. 2021;74:999-1000.
    PubMed    


  406. MORENO C, Sheron N, Tiniakos D, Lackner C, et al
    "Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
    J Hepatol. 2021;74:979-982.
    PubMed    


  407. BAFFY G
    Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
    J Hepatol. 2021;74:988.
    PubMed    


  408. XIA M, Zeng H, Wang S, Tang H, et al
    Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
    J Hepatol. 2021;74:974-977.
    PubMed    


  409. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    PubMed    


  410. SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
    Non-alcoholic fatty liver disease: Not time for an obituary just yet!
    J Hepatol. 2021;74:972-974.
    PubMed    


  411. PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
    A new definition for non-alcoholic fatty liver disease.
    J Hepatol. 2021;74:982-983.
    PubMed    


  412. RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
    Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:985-986.
    PubMed    


  413. RIMASSA L, Personeni N, Czauderna C, Foerster F, et al
    Systemic treatment of HCC in special populations.
    J Hepatol. 2021;74:931-943.
    PubMed     Abstract available


  414. COSTA D, Simbrunner B, Jachs M, Hartl L, et al
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    J Hepatol. 2021;74:819-828.
    PubMed     Abstract available


    March 2021
  415. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available


  416. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    PubMed     Abstract available


  417. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    PubMed    


  418. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    PubMed     Abstract available


  419. HARRISON SA, Gawrieh S, Roberts K, Lisanti CJ, et al
    Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00176.
    PubMed     Abstract available


  420. AN YA, Chen S, Deng Y, Wang ZV, et al
    The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00174.
    PubMed     Abstract available


  421. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available


  422. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    PubMed    


  423. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    PubMed    


  424. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available


  425. GEIDL-FLUECK B, Hochuli M, Nemeth A, Eberl A, et al
    Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.
    J Hepatol. 2021 Mar 5. pii: S0168-8278(21)00161.
    PubMed     Abstract available


  426. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" (J Hepatol [2020] 505-515).
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00103.
    PubMed    


  427. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    PubMed    


  428. WANG J, Liu D, Qi X
    A step forward to predict the risk of post-hepatectomy portal hypertension.
    J Hepatol. 2021 Mar 2. pii: S0168-8278(21)00159.
    PubMed    


  429. MEIJNIKMAN AS, Bruin S, Groen AK, Nieuwdorp M, et al
    Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD.
    J Hepatol. 2021;74:748-749.
    PubMed    


  430. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    PubMed     Abstract available


  431. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    PubMed    


  432. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    PubMed     Abstract available


  433. HEINRICH S, Craig AJ, Ma L, Heinrich B, et al
    Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
    J Hepatol. 2021;74:700-715.
    PubMed     Abstract available


  434. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    PubMed    


  435. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    PubMed     Abstract available


  436. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    PubMed     Abstract available


    February 2021
  437. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    


  438. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    PubMed     Abstract available


  439. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    


  440. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  441. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    PubMed     Abstract available


  442. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  443. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    


  444. HARRISON SA, Bashir MR, Lee KJ, Shim-Lopez J, et al
    A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Feb 10. pii: S0168-8278(21)00099.
    PubMed     Abstract available


  445. LIANG B, Zhou Y, Qian M, Xu M, et al
    TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00095.
    PubMed     Abstract available


  446. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available


  447. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  448. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    PubMed    


  449. GUPTA P, Soundararajan R, Patel A, Kumar-M P, et al
    Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00091.
    PubMed     Abstract available


  450. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available


  451. MUSHTAQ K, Khan MU, Iqbal F, Alsoub DH, et al
    NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.
    J Hepatol. 2021;74:482-484.
    PubMed    


  452. JI D, Cheng G, Lau G
    Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
    J Hepatol. 2021;74:484-485.
    PubMed    


  453. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    PubMed    


  454. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    PubMed    


  455. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    PubMed    


  456. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    PubMed    


  457. MANCO R, Itzkovitz S
    Liver zonation.
    J Hepatol. 2021;74:466-468.
    PubMed    


  458. SAWATZKI M, Guller U, Gusewell S, Husarik DB, et al
    Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
    J Hepatol. 2021;74:419-427.
    PubMed     Abstract available


  459. WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
    Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
    J Hepatol. 2021;74:380-393.
    PubMed     Abstract available


  460. WONG F, Piano S, Singh V, Bartoletti M, et al
    Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.
    J Hepatol. 2021;74:330-339.
    PubMed     Abstract available


    January 2021
  461. SONG Q, Wang J, Griffiths A, Song Z, et al
    Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development".
    J Hepatol. 2021 Jan 30. pii: S0168-8278(21)00083.
    PubMed    


  462. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00003.
    PubMed    


  463. WU X, Poulsen KL, Sanz-Garcia C, Huang E, et al
    Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)".
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00014.
    PubMed    


  464. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available


  465. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    PubMed    


  466. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available


  467. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    PubMed    


  468. LONG J, Bian J, Zhao H
    Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00019.
    PubMed    


  469. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    PubMed     Abstract available


  470. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    PubMed     Abstract available


  471. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    PubMed     Abstract available


  472. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    PubMed     Abstract available


  473. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    PubMed    


  474. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    PubMed    


  475. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    PubMed    


  476. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    PubMed    


  477. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    PubMed    


  478. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    PubMed    


  479. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    PubMed    


  480. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    PubMed    


  481. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    PubMed    


  482. COZMESCU AC, Counsell J, Gissen P
    Gene therapies targeting the liver.
    J Hepatol. 2021;74:235-236.
    PubMed    


  483. BOSCH J
    Small diameter shunts should lead to safe expansion of the use of TIPS.
    J Hepatol. 2021;74:230-234.
    PubMed     Abstract available


  484. DWYER BJ, Macmillan MT, Brennan PN, Forbes SJ, et al
    Cell therapy for advanced liver diseases: Repair or rebuild.
    J Hepatol. 2021;74:185-199.
    PubMed     Abstract available


  485. TEO K, Abeysekera KWM, Adams L, Aigner E, et al
    rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
    J Hepatol. 2021;74:20-30.
    PubMed     Abstract available


    December 2020
  486. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    PubMed    


  487. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    PubMed    


  488. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    PubMed    


  489. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    PubMed    


  490. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    PubMed    


  491. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    PubMed    


  492. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    PubMed    


  493. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    PubMed     Abstract available


  494. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    PubMed     Abstract available


  495. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    PubMed    


  496. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    PubMed    


  497. BRESSON-HADNI S, Montange D, Richou C, Brumpt E, et al
    Tobacco, cannabis, and liquorice: Hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis.
    J Hepatol. 2020 Dec 10. pii: S0168-8278(20)33749.
    PubMed    


  498. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    PubMed     Abstract available


  499. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    PubMed     Abstract available


  500. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    PubMed    


  501. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    PubMed    


  502. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    PubMed    


  503. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available


  504. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available


  505. MARTINEZ-CHANTAR ML, Foti M
    NFATc4: New hub in NASH development.
    J Hepatol. 2020;73:1313-1315.
    PubMed    


  506. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    PubMed    


  507. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    PubMed    


  508. MOSCA A, Panera N, Maggiore G, Alisi A, et al
    From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
    J Hepatol. 2020;73:1590-1592.
    PubMed    


  509. GOH BKP
    Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2020;73:1576.
    PubMed    


  510. HOBEIKA C, Fuks D
    Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.
    J Hepatol. 2020;73:1577-1578.
    PubMed    


  511. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    PubMed    


  512. MAK LY, Yuen MF, Seto WK
    Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    J Hepatol. 2020;73:1573-1574.
    PubMed    


  513. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    PubMed    


  514. ESLAM M, George J
    Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    J Hepatol. 2020;73:1575.
    PubMed    


  515. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    PubMed    


  516. JALAN R, Arroyo V
    Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
    J Hepatol. 2020;73:1316-1318.
    PubMed    


    November 2020
  517. KUPRIYANOVA Y, Zaharia OP, Bobrov P, Karusheva Y, et al
    Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
    J Hepatol. 2020 Nov 28. pii: S0168-8278(20)33817.
    PubMed     Abstract available


  518. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    PubMed     Abstract available


  519. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    PubMed     Abstract available


  520. DING Q, Ma Y, Lai S, Dou X, et al
    NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33812.
    PubMed    


  521. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    PubMed    


  522. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available


  523. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    PubMed     Abstract available


  524. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    PubMed     Abstract available


  525. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available


  526. GOLSE N, Joly F, Combari P, Lewin M, et al
    Predicting the risk of post-hepatectomy portal hypertension using a digital twin: a clinical proof of concept.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33761.
    PubMed     Abstract available


  527. ARECHEDERRA M, Bazai SK, Abdouni A, Sequera C, et al
    ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33758.
    PubMed     Abstract available


  528. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    PubMed     Abstract available


  529. KUCUKOGLU O, Sowa JP, Mazzolini GD, Syn WK, et al
    Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33746.
    PubMed     Abstract available


  530. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    PubMed    


  531. ANTOINE DJ, Jenkins RE, Dear JW, Williams DP, et al
    Retraction notice to "Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity": J Hepatol 56(2012)1070-1079.
    J Hepatol. 2020;73:1297.
    PubMed    


  532. JOTHIMANI D, Venugopal R, Abedin MF, Kaliamoorthy I, et al
    COVID-19 and the liver.
    J Hepatol. 2020;73:1231-1240.
    PubMed     Abstract available


  533. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    PubMed    


  534. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    PubMed    


  535. UNFRIED JP, Fortes P
    SMIM30, a tiny protein with a big role in liver cancer.
    J Hepatol. 2020;73:1010-1012.
    PubMed    


  536. HUANG J, Kumar R, Wang M, Zhu Y, et al
    MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    J Hepatol. 2020;73:1265-1267.
    PubMed    


  537. ESLAM M, George J
    Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    J Hepatol. 2020;73:1268-1269.
    PubMed    


  538. VAN HEES S, Muyindike W, Erem G, Ocama P, et al
    Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.
    J Hepatol. 2020;73:1271-1273.
    PubMed    


  539. SINGAL AG, Lampertico P, Nahon P
    Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda".
    J Hepatol. 2020;73:1273-1274.
    PubMed    


    October 2020
  540. WANG J, Wang Y, Chu Y, Li Z, et al
    Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.
    J Hepatol. 2020 Oct 30. pii: S0168-8278(20)33739.
    PubMed     Abstract available


  541. CHAN SL
    Hyperprogression in hepatocellular carcinoma: Illusion or reality?
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33669.
    PubMed    


  542. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available


  543. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    PubMed     Abstract available


  544. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    PubMed     Abstract available


  545. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    PubMed    


  546. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    PubMed    


  547. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    PubMed    


  548. ROSE CF, Amodio P, Bajaj JS, Dhiman RK, et al
    Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
    J Hepatol. 2020 Oct 21. pii: S0168-8278(20)30466.
    PubMed     Abstract available


  549. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    PubMed     Abstract available


  550. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    PubMed    


  551. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    PubMed    


  552. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available


  553. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    PubMed     Abstract available


  554. MORIKAWA R, Nakamoto N, Amiya T, Chu PS, et al
    Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33677.
    PubMed     Abstract available


  555. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    PubMed     Abstract available


  556. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    PubMed     Abstract available


  557. KIM TH, Koh YH, Kim BH, Kim MJ, et al
    Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33670.
    PubMed     Abstract available


  558. LIU C, Zha Z, Zhou C, Chen Y, et al
    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33674.
    PubMed     Abstract available


  559. FONDEVILA MF, Mercado-Gomez M, Rodriguez A, Gonzalez-Rellan MJ, et al
    Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33671.
    PubMed    


  560. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    PubMed    


  561. WANG Y, Lu F, Zhao J
    Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".
    J Hepatol. 2020;73:996-998.
    PubMed    


  562. MEHAL WZ
    From mice to humans: Unravelling the genetic levers of NASH.
    J Hepatol. 2020;73:749-751.
    PubMed    


  563. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    PubMed    


  564. HUO TI, Ho SY, Ko CC
    Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.
    J Hepatol. 2020;73:972-973.
    PubMed    


  565. SCHWARZKOPF KM, Eberle L, Uschner FE, Klein S, et al
    Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?
    J Hepatol. 2020;73:980-982.
    PubMed    


  566. TREBICKA J, Gu W, Garcia-Pagan JC, Bosch J, et al
    Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?
    J Hepatol. 2020;73:977-979.
    PubMed    


  567. XIANG X, Hwang S, Gao B
    Reply to: "Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?": The search for an optimal mouse model.
    J Hepatol. 2020;73:982-984.
    PubMed    


  568. ELHENCE A, Kumar R, Shalimar
    Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
    J Hepatol. 2020;73:976-977.
    PubMed    


  569. KIM N, Seong J
    Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".
    J Hepatol. 2020;73:973-974.
    PubMed    


    September 2020
  570. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    PubMed    


  571. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    PubMed    


  572. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    PubMed    


  573. SCHUMACHER N, Yan K, Gandrass M, Muller M, et al
    Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33664.
    PubMed     Abstract available


  574. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    PubMed    


  575. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    PubMed    


  576. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    PubMed    


  577. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Corrigendum to: "Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis" [J Hepatol (2020) 241-251].
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33603.
    PubMed    


  578. SECKLER F, Doussot A, Colpart P, Turco C, et al
    Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)30366.
    PubMed    


  579. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    PubMed     Abstract available


  580. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    PubMed     Abstract available


  581. SCHATTENBERG JM, Straub BK
    On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30475.
    PubMed    


  582. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    PubMed    


  583. KIM N, Cheng J, Jung I, Liang J, et al
    Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    J Hepatol. 2020 Sep 10. pii: S0168-8278(20)33602.
    PubMed    


  584. TONON M, Rosi S, Gambino CG, Piano S, et al
    Natural history of acute kidney disease in patients with cirrhosis.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33612.
    PubMed     Abstract available


  585. CHAN LK, Wai-Hung Ho D, Kam CS, Yung-Tuen Chiu E, et al
    RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33610.
    PubMed     Abstract available


  586. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
    J Hepatol. 2020 Sep 7. pii: S0168-8278(20)33591.
    PubMed    


  587. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    PubMed    


  588. MERLI M
    Nutrition in cirrhosis: Dos and Don'ts.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30474.
    PubMed    


  589. SERPER M, Shaked A, Olthoff KM, Hoteit M, et al
    A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.
    J Hepatol. 2020;73:708-709.
    PubMed    


  590. VALENTI L, Jamialahmadi O, Romeo S
    Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
    J Hepatol. 2020;73:709-711.
    PubMed    


  591. DI GIORGIO A, Nicastro E, Speziani C, De Giorgio M, et al
    Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.
    J Hepatol. 2020;73:702-705.
    PubMed    


  592. JI D, Xu J, Qin E, Zhang D, et al
    Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.
    J Hepatol. 2020;73:718-719.
    PubMed    


  593. BIQUARD L, Valla D, Rautou PE
    No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
    J Hepatol. 2020;73:717-718.
    PubMed    


  594. RICKE J, Sangro B, Malfertheiner P, Seidensticker M, et al
    Reply to: "Toxicity and dosimetry in SORAMIC study".
    J Hepatol. 2020;73:735-736.
    PubMed    


  595. REINDERS M, Braat A, Lam M
    Toxicity and dosimetry in SORAMIC study.
    J Hepatol. 2020;73:734-735.
    PubMed    


  596. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    PubMed    


  597. PAISANT A, Vilgrain V, Aube C
    Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    J Hepatol. 2020;73:716-717.
    PubMed    


  598. CHOI SH, Kim SY, Lim YS
    Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    J Hepatol. 2020;73:714-715.
    PubMed    


  599. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    PubMed    


  600. GUIU B
    Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.
    J Hepatol. 2020;73:727-728.
    PubMed    


  601. JI D, Zhang D, Lau G
    Reply to: 'NAFLD or comorbidities, that is the question'.
    J Hepatol. 2020;73:724-725.
    PubMed    


  602. PONZIANI FR, Gasbarrini A, Pompili M
    NAFLD or comorbidities, that is the question.
    J Hepatol. 2020;73:723.
    PubMed    


    August 2020
  603. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    PubMed    


  604. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    PubMed    


  605. CARACENI P, Tufoni M, Zaccherini G, Riggio O, et al
    On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)33551.
    PubMed     Abstract available


  606. XU Z, Li H, Tian S, Wu J, et al
    Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30371.
    PubMed    


  607. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30442.
    PubMed    


  608. YOSHIZUMI T, Itoh S, Shimokawa M, Inokuchi S, et al
    Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.
    J Hepatol. 2020 Aug 19. pii: S0168-8278(20)30547.
    PubMed     Abstract available


  609. FAN L, Lai R, Ma N, Dong Y, et al
    miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30541.
    PubMed     Abstract available


  610. RHEE H, Cho ES, Nahm JH, Jang M, et al
    Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30544.
    PubMed     Abstract available


  611. LINE PD, Dueland S
    Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
    PubMed    


  612. KIM CG, Kim C, Yoon SE, Kim KH, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Aug 15. pii: S0168-8278(20)30540.
    PubMed     Abstract available


  613. MANNING C, Alam SM
    Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30380.
    PubMed    


  614. SOLA E, Pose E, Campion D, Piano S, et al
    ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30536.
    PubMed     Abstract available


  615. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    PubMed     Abstract available


  616. IAVARONE M, D'Ambrosio R, Lampertico P
    Authors' reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19.
    J Hepatol. 2020 Aug 6. pii: S0168-8278(20)30524.
    PubMed    


  617. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    PubMed    


  618. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    PubMed     Abstract available


  619. JI D, Qin E, Xu J, Zhang D, et al
    Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
    J Hepatol. 2020;73:451-453.
    PubMed    


  620. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    PubMed    


  621. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    PubMed    


  622. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    PubMed    


    July 2020
  623. KOMOLL RM, Hu Q, Olarewaju O, von Dohlen L, et al
    MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    J Hepatol. 2020 Jul 30. pii: S0168-8278(20)30492.
    PubMed     Abstract available


  624. LUO YD, Fang L, Yu HQ, Zhang J, et al
    p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
    J Hepatol. 2020 Jul 29. pii: S0168-8278(20)30489.
    PubMed     Abstract available


  625. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available


  626. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    PubMed     Abstract available


  627. SANGRO B, Melero I, Wadhawan S, Finn RS, et al
    Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Jul 22. pii: S0168-8278(20)30479.
    PubMed     Abstract available


  628. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    PubMed     Abstract available


  629. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    PubMed     Abstract available


  630. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30388.
    PubMed    


  631. XU G, Xiao Y, Jin B, Sang X, et al
    Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30343.
    PubMed    


  632. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    PubMed     Abstract available


  633. SONG Y, An O, Ren X, Man Chan TH, et al
    RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.
    J Hepatol. 2020 Jul 18. pii: S0168-8278(20)30476.
    PubMed     Abstract available


  634. ZHANG X, Fan L, Wu J, Xu H, et al
    Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)".
    J Hepatol. 2020 Jul 17. pii: S0168-8278(20)30390.
    PubMed    


  635. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    PubMed    


  636. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez-Guerra M, et al
    Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30456.
    PubMed     Abstract available


  637. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    PubMed     Abstract available


  638. MCPHAIL MJW, Coen M
    Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30183.
    PubMed    


  639. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120).
    J Hepatol. 2020 Jul 10. pii: S0168-8278(20)30384.
    PubMed     Abstract available


  640. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
    J Hepatol. 2020 Jul 9. pii: S0168-8278(20)30389.
    PubMed    


  641. MOREAU R, Aguilar F, Arroyo V
    Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis".
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30340.
    PubMed    


  642. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    PubMed    


  643. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    PubMed    


  644. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    PubMed    


  645. LAZARUS JV, Cortez-Pinto H, Anstee QM
    Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:221-222.
    PubMed    


  646. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    PubMed    


  647. LEUNG M, Piao C, Sarkar S
    NAFLD referral patterns in a large US academic center.
    J Hepatol. 2020;73:218-219.
    PubMed    


  648. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    PubMed    


  649. MENDEZ-SANCHEZ N, Valencia-Rodriguez A
    Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:220.
    PubMed    


  650. ZOU ZY, Fan JG
    Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:214-216.
    PubMed    


    June 2020
  651. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    PubMed     Abstract available


  652. DONG P, Wang X, Liu L, Tang W, et al
    Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    J Hepatol. 2020 Jun 28. pii: S0168-8278(20)30400.
    PubMed     Abstract available


  653. RUART M, Chavarria L, Camprecios G, Suarez-Herrera N, et al
    Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469].
    J Hepatol. 2020 Jun 27. pii: S0168-8278(20)30354.
    PubMed    


  654. LAMPL S, Janas MK, Donakonda S, Brugger M, et al
    Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30398.
    PubMed     Abstract available


  655. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    PubMed    


  656. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    PubMed    


  657. BASSEGODA O, Sola E, Gines P
    Reply to: "Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions".
    J Hepatol. 2020 Jun 21. pii: S0168-8278(20)30287.
    PubMed    


  658. GAO F, Huang ZM
    The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30397.
    PubMed    


  659. MEDHAT MA, El Kassas M
    Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19].
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30396.
    PubMed    


  660. KUMAR R, Kerbert AJC, Sheikh MF, Roth N, et al
    Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30381.
    PubMed     Abstract available


  661. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available


  662. COLNOT S, Lechel A
    Maternal obesity: A severe risk factor in hepatocarcinogenesis?
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30385.
    PubMed    


  663. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed     Abstract available


  664. SINGH I, De A, Singh V
    Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30184.
    PubMed    


  665. RAI RP, Liu Y, Iyer SS, Liu S, et al
    Blocking integrin alpha4beta7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30375.
    PubMed     Abstract available


  666. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    PubMed     Abstract available


  667. IAVARONE M, D'Ambrosio R, Soria A, Triolo M, et al
    High rates of 30-day mortality in patients with cirrhosis and COVID-19.
    J Hepatol. 2020 Jun 8. pii: S0168-8278(20)30365.
    PubMed     Abstract available


  668. JEPSEN P, Kraglund F, West J, Villadsen GE, et al
    Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
    J Hepatol. 2020 Jun 5. pii: S0168-8278(20)30363.
    PubMed     Abstract available


  669. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available


  670. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    PubMed    


  671. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    PubMed     Abstract available


  672. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    PubMed     Abstract available


  673. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    PubMed    


  674. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    PubMed    


  675. EDELINE J, Garin E
    Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90....
    J Hepatol. 2020;72:1046-1048.
    PubMed    


  676. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    PubMed    


  677. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    PubMed    


  678. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    PubMed    


  679. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    PubMed    


    May 2020
  680. DE SMET V, Verhulst S, van Grunsven LA
    Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2.
    J Hepatol. 2020 May 27. pii: S0168-8278(20)30349.
    PubMed    


  681. LUUKKONEN PK, Juuti A, Sammalkorpi H, Penttila AK, et al
    MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30234.
    PubMed    


  682. KIM N, Seong J
    Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
    J Hepatol. 2020 May 25. pii: S0168-8278(20)30229.
    PubMed    


  683. CHEW CA, Iyer SG, Chieh Kow AW, Madhavan K, et al
    An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.
    J Hepatol. 2020 May 23. pii: S0168-8278(20)30342.
    PubMed     Abstract available


  684. TELLEZ L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, et al
    Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30303.
    PubMed     Abstract available


  685. MOON AM, Webb GJ, Aloman C, Armstrong MJ, et al
    High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.
    J Hepatol. 2020 May 20. pii: S0168-8278(20)30305.
    PubMed    


  686. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    PubMed    


  687. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    PubMed    


  688. LUCIFORA J, Michelet M, Rivoire M, Protzer U, et al
    Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30204.
    PubMed    


  689. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    PubMed    


  690. GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
    FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
    PubMed     Abstract available


  691. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    PubMed    


  692. KUMAR A
    Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30175.
    PubMed    


  693. PENG ZP, Jiang ZZ, Guo HF, Zhou MM, et al
    Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30296.
    PubMed     Abstract available


  694. WANG Y, Liu S, Liu H, Li W, et al
    SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30294.
    PubMed     Abstract available


  695. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    PubMed    


  696. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    PubMed     Abstract available


  697. DESAI AP, Knapp SM, Orman ES, Ghabril MS, et al
    Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30289.
    PubMed     Abstract available


  698. MEYER T
    Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30232.
    PubMed    


  699. DAI Z, Ott M, Sharma AD
    Equal opportunity offer for all hepatocytes.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30200.
    PubMed    


  700. SCHWERBEL K, Kamitz A, Krahmer N, Hallahan N, et al
    Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30275.
    PubMed     Abstract available


  701. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    PubMed     Abstract available


  702. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available


  703. ABE H, Schuppan D
    beta-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.
    J Hepatol. 2020;72:813-815.
    PubMed    


    April 2020
  704. SERENARI M, Han KH, Ravaioli F, Kim SU, et al
    A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Apr 30. pii: S0168-8278(20)30276.
    PubMed     Abstract available


  705. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    PubMed     Abstract available


  706. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30214.
    PubMed    


  707. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


  708. FORREST E
    Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30117.
    PubMed    


  709. DEGRE D, Stauber RE, Deltenre P, Lackner C, et al
    Reply to: "Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30199.
    PubMed    


  710. OKINA Y, Sato-Matsubara M, Matsubara T, Daikoku A, et al
    TGF-beta-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.
    J Hepatol. 2020 Apr 17. pii: S0168-8278(20)30228.
    PubMed     Abstract available


  711. TAPPER EB, Asrani SK
    COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30217.
    PubMed     Abstract available


  712. TAPIAS EA, Ardevol A, Garcia-Guix M, Montanes R, et al
    Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30211.
    PubMed     Abstract available


  713. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213.
    PubMed     Abstract available


  714. LOPEZ-VICARIO C, Checa A, Urdangarin A, Aguilar F, et al
    Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30208.
    PubMed     Abstract available


  715. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available


  716. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    PubMed     Abstract available


  717. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30016.
    PubMed    


  718. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    PubMed    


  719. GANNE-CARRIE N, Piscaglia F
    Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?
    J Hepatol. 2020;72:607-609.
    PubMed    


  720. ENGELMANN C, Mehta G, Tacke F
    Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.
    J Hepatol. 2020;72:610-612.
    PubMed    


    March 2020
  721. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed     Abstract available


  722. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    PubMed     Abstract available


  723. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    PubMed     Abstract available


  724. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    PubMed     Abstract available


  725. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    PubMed     Abstract available


  726. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    PubMed     Abstract available


  727. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    PubMed    


  728. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.
    PubMed    


  729. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    PubMed    


  730. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    PubMed     Abstract available


  731. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available


  732. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    PubMed     Abstract available


  733. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed     Abstract available


  734. WONG VW
    Predicting NASH response with liver fat: Are we back to square one?
    J Hepatol. 2020;72:386-388.
    PubMed    


    February 2020
  735. ARFIANTI A, Pok S, Barn V, Haigh WG, et al
    Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30104.
    PubMed     Abstract available


  736. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available


  737. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    PubMed     Abstract available


    January 2020
  738. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    PubMed     Abstract available


  739. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    PubMed     Abstract available


  740. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    PubMed     Abstract available


    December 2019
  741. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available


  742. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    PubMed     Abstract available


  743. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    PubMed     Abstract available


    November 2019
  744. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    PubMed     Abstract available


  745. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    PubMed     Abstract available


    October 2019
  746. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    PubMed     Abstract available


  747. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    PubMed     Abstract available


  748. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    PubMed     Abstract available


    August 2019
  749. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    PubMed     Abstract available


    June 2019
  750. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    PubMed     Abstract available


  751. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    PubMed     Abstract available


  752. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    PubMed     Abstract available


    May 2019
  753. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    PubMed     Abstract available


    April 2019
  754. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    PubMed     Abstract available


    March 2019
  755. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    PubMed     Abstract available


  756. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    PubMed     Abstract available


    December 2018
  757. ICHAI P, Laurent-Bellue A, Camus C, Moreau D, et al
    Liver transplantation in patients with liver failure related to exertional heatstroke.
    J Hepatol. 2018 Dec 3. pii: S0168-8278(18)32575.
    PubMed     Abstract available


    November 2018
  758. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Abstract available


    July 2018
  759. LAUTERIO A, Moioli MC, Di Sandro S, Travi G, et al
    HIV-positive to HIV-positive liver transplantation: To be continued.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32180.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: